Potential Role of Induced Pluripotent Stem Cells (IPSCs) for Cell-Based Therapy of the Ocular Surface

• Main Authors: Ricardo P. Casaroli-Marano, Núria Nieto-Nicolau, Eva M. Martínez-Conesa, Michael Edel, Ana B.Álvarez-Palomo
• Format: Article
• Language: English
• Published: MDPI AG 2015-02-01
• Series: Journal of Clinical Medicine
• Subjects: limbal stem cells; cornea; limbal stem cell deficiency; epithelial differentiation; human adult progenitor cells; ex vivo expansion; cell culture; ocular burns; cell-based therapy; human stem cells
• Online Access: http://www.mdpi.com/2077-0383/4/2/318

The integrity and normal function of the corneal epithelium are crucial for maintaining the cornea’s transparency and vision. The existence of a cell population with progenitor characteristics in the limbus maintains a dynamic of constant epithelial repair and renewal. Currently, cell-based therapies for bio replacement—cultured limbal epithelial transplantation (CLET) and cultured oral mucosal epithelial transplantation (COMET)—present very encouraging clinical results for treating limbal stem cell deficiency (LSCD) and restoring vision. Another emerging therapeutic approach consists of obtaining and implementing human progenitor cells of different origins in association with tissue engineering methods. The development of cell-based therapies using stem cells, such as human adult mesenchymal or induced pluripotent stem cells (IPSCs), represent a significant breakthrough in the treatment of certain eye diseases, offering a more rational, less invasive, and better physiological treatment option in regenerative medicine for the ocular surface. This review will focus on the main concepts of cell-based therapies for the ocular surface and the future use of IPSCs to treat LSCD.